Boston Scientific Corp (BSX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Total Revenue Chart for Boston Scientific Corp

Boston Scientific Corp (BSX) revenue for FY2025 was USD 20.1B, a 19.9% change from FY2024. Boston Scientific Corp's revenue grew from USD 230.0M in 1991 to USD 20.1B in 2025 (8627.8% over 34 years). Earnings per share grew from USD 0.45 in 2000 to USD 1.94 in 2025 (326.2%). Revenue compound annual growth rate: 5-year CAGR of 15.2%, 10-year CAGR of 10.4%, 20-year CAGR of 6.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$71.45B
Implied Share Price
$49.30
Enterprise Value
$83.23B
Revenue (TTM)
$21.00B
EBITDA
$5.71B
Profit Margin
17.50%
Trailing P/E
19.33
Forward P/E
14.93
Price/Book (MRQ)
2.85
Price/Sales (TTM)
3.40
EV/EBITDA
14.76
EV/Revenue
3.96
Dividend Yield
—
Book Value
$17.23
Free Cash Flow (FY2025)
$3.66B
Free Cash Flow Yield
5.12%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.